Theralase Technologies (CVE:TLT) Hits New 52-Week High - Should You Buy?

Key Points

• New 52-week high: Theralase Technologies (CVE:TLT) reached C$0.37 on Friday, trading up about 7.2% with volume of 248,713 shares from a prior close of C$0.35.
• Mixed fundamentals: The company has a market cap of C$99.58 million, negative earnings (P/E -20.56), a high debt-to-equity ratio of 29.26, and mixed liquidity metrics (current ratio 0.83, quick ratio 3.40).
• Business focus: Theralase is a clinical-stage pharmaceutical company developing light-activated photo dynamic compounds (PDCs) for cancers, bacteria and viruses, and sells patented super-pulsed laser technology for chronic knee pain and related conditions.

Theralase Technologies Inc. (CVE:TLT - ) reached a new 52-week high during mid-day trading on Friday . The company traded as high as C$0.37 and last traded at C$0.37, with a volume of 248713 shares. The stock had previously closed at C$0.35.

Theralase Technologies Trading Up 7.2%

The business's 50 day moving average price is C$0.29 and its 200-day moving average price is C$0.23. The company has a current ratio of 0.83, a quick ratio of 3.40 and a debt-to-equity ratio of 29.26. The company has a market cap of C$99.58 million, a price-to-earnings ratio of -20.56 and a beta of -0.31.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.